ストックスクリーナーアプリを入手
24.30
7.05%
1.61
前日終値:
$22.69
開ける：
$22.78
24時間の取引高:
187.82K
Relative Volume:
0.35
時価総額：
$1.56B
収益：
$71.30M
当期純損益:
$-354.80M
株価収益率:
-4.347
EPS:
-5.59
ネットキャッシュフロー:
$-356.00M
1週間 パフォーマンス:
-2.53%
1か月 パフォーマンス:
-5.71%
6か月 パフォーマンス:
-29.90%
1年 パフォーマンス:
+16.78%
1日の値動き範囲:
$22.57
$24.44
1週間の範囲:
$21.17
$25.10
52週間の値動き範囲:
$20.99
$53.08
Arvinas Inc Stock (ARVN) Company Profile
ARVN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| ARVN | 24.29 | 1.56B | 71.30M | -354.80M | -356.00M | -5.59 |
| VRTX | 447.37 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.48 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 592.30 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.75 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 104.10 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-02-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-02-01 | 開始されました | Goldman | Buy |
| 2023-12-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | アップグレード | Jefferies | Hold → Buy |
| 2023-11-20 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-10-23 | アップグレード | Wedbush | Neutral → Outperform |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2023-01-12 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-01-03 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | 開始されました | Barclays | Overweight |
| 2022-06-21 | 開始されました | Jefferies | Hold |
| 2022-05-09 | ダウングレード | Wedbush | Outperform → Neutral |
| 2022-04-28 | 開始されました | Credit Suisse | Outperform |
| 2022-04-06 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-02-11 | 再開されました | BMO Capital Markets | Outperform |
| 2022-02-10 | 開始されました | Wells Fargo | Overweight |
| 2022-01-19 | 開始されました | Goldman | Buy |
| 2021-12-07 | 開始されました | Cowen | Outperform |
| 2021-10-14 | 開始されました | SVB Leerink | Outperform |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-09-09 | 開始されました | BofA Securities | Buy |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-21 | 開始されました | Truist | Buy |
| 2021-03-31 | 開始されました | BMO Capital Markets | Outperform |
| 2020-12-14 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-06-01 | アップグレード | Citigroup | Neutral → Buy |
| 2020-05-12 | 開始されました | Oppenheimer | Perform |
| 2019-12-19 | 開始されました | H.C. Wainwright | Buy |
| 2019-11-25 | 開始されました | Guggenheim | Buy |
| 2019-10-24 | アップグレード | Goldman | Neutral → Buy |
| 2019-09-25 | 開始されました | Wedbush | Outperform |
| 2019-09-12 | 開始されました | BMO Capital Markets | Outperform |
| 2019-08-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-06-05 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2018-10-22 | 開始されました | Citigroup | Buy |
| 2018-10-22 | 開始されました | Goldman | Neutral |
| 2018-10-22 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Arvinas Inc (ARVN) 最新ニュース
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Investors to Reach Out - AccessWire
(ARVN) Technical Pivots with Risk Controls - Stock Traders Daily
Arvinas stock remains a Top Pick despite slight reduction in price target, says BMO - Investing.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Stockholders to Reach Out - AccessWire
Unveiling 4 Analyst Insights On Arvinas - Benzinga
Arvinas shares target cut to $62 on delayed trial data - Investing.com
Arvinas reports delay in breast cancer trial results - Investing.com India
Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode - Insider Monkey
Pfizer, Arvinas delay late-stage trial for breast cancer therapy - Seeking Alpha
Stephens Begins Coverage on Arvinas (NASDAQ:ARVN) - MarketBeat
Short Interest in Arvinas, Inc. (NASDAQ:ARVN) Drops By 5.6% - MarketBeat
Stephens & Co. Initiates Coverage of Arvinas (ARVN) with Overweight Recommendation - MSN
RTW INVESTMENTS, LP Adjusts Stake in Arvinas Inc - GuruFocus.com
Arvinas chief accounting officer David Loomis sells $10,300 in stock By Investing.com - Investing.com Australia
Arvinas chief accounting officer David Loomis sells $10,300 in stock - Investing.com
How the (ARVN) price action is used to our Advantage - Stock Traders Daily
Arvinas, Inc. (NASDAQ:ARVN) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Arvinas, Inc. (NASDAQ:ARVN) Receives $56.92 Consensus Target Price from Analysts - MarketBeat
Arvinas (ARVN) Stock Price, News & Analysis - MarketBeat
Arvinas's SWOT analysis: biotech stock poised for pivotal trial results - Investing.com India
Arvinas's SWOT analysis: biotech stock poised for pivotal trial results By Investing.com - Investing.com Canada
Allspring Global Investments Holdings LLC Has $182,000 Stake in Arvinas, Inc. (NASDAQ:ARVN) - Defense World
Arvinas to Participate in Upcoming Investor Conferences - GlobeNewswire
Arvinas (NASDAQ:ARVN) Receives Buy Rating from HC Wainwright - Defense World
FY2024 EPS Estimates for Arvinas Reduced by Leerink Partnrs - MarketBeat
Wedbush Issues Pessimistic Estimate for Arvinas Earnings - Defense World
FY2024 EPS Estimates for Arvinas Cut by Leerink Partnrs - Defense World
Arvinas (NASDAQ:ARVN) Price Target Lowered to $40.00 at Oppenheimer - Defense World
Arvinas Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Oppenheimer cuts Arvinas shares price target to $40 ahead of TACTIVE-U trial - Investing.com
Arvinas' (ARVN) Buy Rating Reiterated at HC Wainwright - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Q3 2024 Earnings Call Transcript - Insider Monkey
Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates - MSN
Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Reve - GuruFocus.com
Assenagon Asset Management S.A. Invests $3.44 Million in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Promising ... - Yahoo Finance
Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Promising ... By GuruFocus - Investing.com Canada
Arvinas Reports Progress in Q3 2024 Financials and Trials - TipRanks
Arvinas Inc (ARVN) Q3 2024 Earnings: Revenue Soars to $102.4M, B - GuruFocus.com
Arvinas (NASDAQ:ARVN) Trading 4.3% HigherTime to Buy? - MarketBeat
Arvinas earnings beat by $0.16, revenue topped estimates - Investing.com Canada
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Arvinas, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Arvinas Inc (ARVN) Q3 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
Arvinas, Inc. (NASDAQ:ARVN) Short Interest Down 12.7% in October - MarketBeat
We're Hopeful That Arvinas (NASDAQ:ARVN) Will Use Its Cash Wisely - Yahoo Finance
Arvinas (ARVN): A Small-Cap Biotech with High Growth Potential - Insider Monkey
Arvinas (ARVN) to Release Earnings on Wednesday - MarketBeat
8 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey
Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day - ForexTV.com
Arvinas Inc (ARVN) 財務データ
収益
当期純利益
現金流量
EPS
Arvinas Inc (ARVN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Houston John G | President and CEO |
Feb 23 '24 |
Sale |
47.05 |
5,196 |
244,472 |
1,036,681 |
| Cassidy Sean A | Chief Financial Officer |
Feb 23 '24 |
Sale |
47.05 |
1,702 |
80,079 |
181,916 |
| Peck Ronald | Chief Medical Officer |
Feb 23 '24 |
Sale |
47.05 |
1,699 |
79,938 |
67,516 |
| Taylor Ian | Chief Scientific Officer |
Feb 23 '24 |
Sale |
47.05 |
1,701 |
80,032 |
147,522 |
| Taylor Ian | Chief Scientific Officer |
Jan 04 '24 |
Option Exercise |
16.00 |
8,252 |
132,032 |
109,973 |
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):